Verona Pharma PLC (VRP)

Back to homepage

Company Description

Verona Pharma PLC was incorporated on February 24, 2005. On 18 September 2006 the Company acquired all the shares of Rhinopharma Ltd and changed its name to Verona Pharma PLC. The Company is a development stage company, engaged in novel, first-in-class drugs for patients suffering from respiratory diseases with high unmet medical need; products for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cough. The Company has three main products: RPL554, VRP700 and NAIPs. RPL554 and VRP700 are in the clinical phase, RPL554 has successfully completed Phase I and II trials, VRP700 has successfully completed a Phase II trial, and NAIPs is in the basic research phase. RPL554 is a dual phosphodiesterase 3 and 4 inhibitor selected for clinical development and is being developed as a potential treatment for patients with chronic respiratory diseases such as COPD and asthma. The Company operates in United Kingdom and Canada...